Table 2. Baseline Characteristics a of 4,516 Individuals with Diabetes Mellitus from the European Prospective Investigation into Cancer and Nutrition by Type of Medication Use.
| Diabetes medication | % | Age (y) | Mean difference HbA1c (%)b | Disease duration (y) | BMI (kg/m2) | Co-morbidities (%) |
| None | 31 | 56.8 (6.6) | −0.7 | 5.8 (6.1) | 29.2 (4.7) | 12 |
| Metformin (monotherapy) | 5 | 57.9 (6.8) | 0 | 6.5 (6.0) | 30.4 (4.8) | 12 |
| Metformin (combined) | 11 | 58.6 (7.1) | +0.8 | 9.1 (7.2) | 29.6 (4.6) | 14 |
| Sulfonamides | 19 | 59.4 (6.9) | +0.6 | 8.3 (6.6) | 28.7 (4.5) | 18 |
| Combinations or other OHA | 7 | 57.8 (6.3) | +0.3 | 7.6 (7.0) | 29.8 (5.4) | 15 |
| Insulin and OHA combined | 7 | 58.1 (6.0) | +0.6 | 10.7 (8.7) | 29.8 (4.9) | 14 |
| Insulin therapy | 19 | 55.9 (8.3) | +0.9 | 14.7 (10.8) | 27.2 (4.9) | 18 |
Abbreviations: BMI, body mass index; OHA, oral hypoglycemic agent.
a
Means (SE) or percentages are shown;
b
Mean differences in HbA1c values are given compared with metformin monotherapy.